Ways to improve the therapy of escerichosis in children infected with Epstein-Barr virus
DOI:
https://doi.org/10.24959/cphj.17.1443Keywords:
escherihiosis, Epstein-Barr virus, children, treatmentAbstract
Pathogenic escherichia in young children remains one of the main factors of bacterial lesions of the gastrointestinal tract.
Aim. To study the effectiveness of the use of interferons in the treatment of escherichiosis in children infected with Epstein-Barr virus (EBV).
Materials and methods. At the premises of the Regional Children Infectious Clinical Hospital of Kharkiv a comparison of dynamics of the clinical and laboratory parameters of 68 children aged 1-3 years old with a moderate form of escherichiosis and infected with EBV (inactive persistent form) was performed. The first group consisted of 47 children whose treatment was carried out according to the generally accepted schemes; the second group was 21 children receiving recombinant interferon alfa-2 in the complex therapy in the age-related doses twice a day for 5 days.
Results. Significant difference within the time of fever preservation (4.73±0.37 versus 3.25 ± 0.21 days, p<0.01) and disappearance of the general intoxication symptoms (4.02 ± 0.29 vs. 2.24 ± 0.35, p<0.01) were determined. According to the ultrasound study normalization of defecation (5.91 ± 0.22 vs. 4.34 ± 0.29 days, p<0.01) and elimination of signs of the parenchymal liver reaction (5.94 ± 0.39 vs. 4.15 ± 0.50 days, p<0.05), as well as mezadenite phenomena (8.67 ± 0.86 vs. 6.19 ± 0.77 days, respectively, p<0.05) were statistically significant in children of the first group. The positive effect of interferon therapy on the parameters of the clinical blood analysis was manifested in the faster normalization of the amount of leukocytes and ESR (7.55 ± 0.61 vs. 5.44 ± 0.48 days, p<0.05). In general, duration of patient’s staying at hospital in children of the first group was 10.64 ± 0.53 days, while in the second group it was 8.09 ± 0.36 days, p<0.01.
Conclusions. The use of recombinant interferon alfa-2 in the complex therapy of escherichiosis in children infected with EBV positively affects the regression of clinical manifestations, accelerates normalization of the laboratory and instrumental indices, and reduces duration of patient’s staying at hospital.
References
Pronko, N. V., Danilevich, N. A., Koniuk, L. A. (2014). Zhurnal Grodnenskogo gosudarstvennogo meditcinskogo universiteta, 3, 92–95.
Pronko, N. V. Tcyrkunov, V. M., Yakusevich, T. V. (2016). Aktualnaia infektologiia, 3, 100–105.
Croxen, M. A., Law, R. J., Scholz, R., Keeney, K. M., Wlodarska, M., Finlay, B. B. (2013). Recent Advances in Understanding Enteric Pathogenic Escherichia coli. Clinical Microbiology Reviews, 26 (4), 822–880. doi: 10.1128/cmr.00022–13
WHO : The top 10 causes of death (2014). Fact sheet ¹ 310. Available at: http://www.who.int/mediacentre/factshee ts/fs310/en/
Hold, G. L., Mukhopadhya, I., Monie, T. P. (2011). Innate Immune Sensors and Gastrointestinal Bacterial Infections. Clinical and Developmental Immunology, 2011, 1–11. doi: 10.1155/2011/579650
Bolis, V., Karadedos, C., Chiotis, I., Chaliasos, N., Tsabouri, S. (2016). Atypical manifestations of Epstein–Barr virus in children: a diagnostic challenge. Jornal de Pediatria, 92 (2), 113–121. doi:10.1016/j.jped.2015.06.007
Tyunyaeva, N., Sofronova, L. (2014). Infectious Mononucleosis: Etiological Factors, Diagnosis and Treatment Problems. Journal of New Medical Technologies, 21 (3), 184–191. doi:10.12737/5932
Klimova, R. R. (2014). Pediatriia, 93 (1), 32–37.
Kasymova, E. B., Bashkina, O. A., Galimzianov, H. M. (2016). Novaia nauka: sovremennoe sostoianie i puti razvitiia 98 (8), 16–20.
Barycheva, L. Yu., Golubeva, M. V., Volkova, A. V. (2014). Detskie infektcii, 2, 28–33.
Order № 354, 09.07.2004 «On approval of protocols for diagnosis and treatment of infectious diseases in children». Available at: http://mozdocs.kiev.ua/view.php?id=3292
Simovanian, E. N. (2016). Detskie infektcii, 1 (15), 15–23.
Bulgakova, V. A. (2014). Zdorove rebenka, 2, 78–84.
Shtro, A. A., Slita, A. V., Carpinskaia, L. A. et al. (2012). Interferon activity in combination with antioxidants against DNA and RNA–containing Human viruses. Lechashchii vrach, 10, 22–26.
Gorelov, A. V., Alimova, I. L., Antonova, T. I., Feklisova, L. V. et al. (2015). Interferon preparations in therapy of acute respiratory viral infections and flu in newborns and infants. Lechashchii vrach, 1, 7–14.
Downloads
Published
Issue
Section
License
Copyright (c) 2017 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
